In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

Pioneering Partnerships And Novel Trial Design Are Reshaping Repurposing In The CNS Space

Major Repurposing Projects Are Underway Across Multiple Disease Areas

Executive Summary

Repurposing licensed drugs can be an affordable and effective way to bring new treatments to market, but initial efforts tend to lack funding from big pharma. In Vivo takes a closer look at repurposing projects across the central nervous system space, what it is that drives the work forward and how innovative trial design is changing the game.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel